Crinetics Pharmaceuticals CRNX Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax?
- Crinetics Pharmaceuticals (CRNX) reported other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax of $28K in Q1 2026.
- How has Crinetics Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax changed year-over-year?
- Crinetics Pharmaceuticals's other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax increased by 366.7% year-over-year, from $6K to $28K.
- What does other comprehensive income foreign currency transaction and translation gain loss arising during period net of tax mean?
- This captures the net gains or losses resulting from the translation of financial statements denominated in foreign currencies or from foreign currency transactions. It reflects the impact of exchange rate fluctuations on the company's international financial exposure. Monitoring this helps investors isolate the effects of currency volatility from the company's core operational performance.